Global Long-acting DPP-4 Inhibitor Drug Market Growth (Status and Outlook) 2024-2030

Global Long-acting DPP-4 Inhibitor Drug Market Growth (Status and Outlook) 2024-2030


Long-acting dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of drugs used to treat type 2 diabetes. They are characterized by a long half-life and extended duration of action, with some formulations allowing for once-weekly dosing and others even every two weeks.

The global Long-acting DPP-4 Inhibitor Drug market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Long-acting DPP-4 Inhibitor Drug Industry Forecast” looks at past sales and reviews total world Long-acting DPP-4 Inhibitor Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Long-acting DPP-4 Inhibitor Drug sales for 2023 through 2029. With Long-acting DPP-4 Inhibitor Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting DPP-4 Inhibitor Drug industry.

This Insight Report provides a comprehensive analysis of the global Long-acting DPP-4 Inhibitor Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long-acting DPP-4 Inhibitor Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting DPP-4 Inhibitor Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting DPP-4 Inhibitor Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting DPP-4 Inhibitor Drug.

United States market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Long-acting DPP-4 Inhibitor Drug players cover Merck & Co, Takeda Pharmaceutical, Furiex, Beacon Pharma, Kelun Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting DPP-4 Inhibitor Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:
Weekly
Biweekly

Segmentation by Application:
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Weekly
Biweekly

Segmentation by Application:
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck & Co
Takeda Pharmaceutical
Furiex
Beacon Pharma
Kelun Pharmaceutical
Haisco Pharmaceutical
Easton Biopharmaceuticals
Baiji Dichang Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.


*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Long-acting DPP-4 Inhibitor Drug Market Size by Player
4 Long-acting DPP-4 Inhibitor Drug by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Long-acting DPP-4 Inhibitor Drug Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings